<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942250</url>
  </required_header>
  <id_info>
    <org_study_id>2222018NCRRT</org_study_id>
    <nct_id>NCT03942250</nct_id>
  </id_info>
  <brief_title>Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients</brief_title>
  <official_title>Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Egyptian Atomic Energy Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Egyptian Atomic Energy Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of human amniotic membrane as a weekly dressing on chronic wounds in
      Epidermolysis Bullosa (EB) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dried human amniotic membrane dressing were obtained from National center for radiation
      research and technology, Egypt (NCRRT), under commercial name REGE pro.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion area</measure>
    <time_frame>6 weeks</time_frame>
    <description>The lesion area from the first treatment is greater than 2 cm^2 (grade 3, according to CTCAE v4.0), to the complete healing (= 0 cm^2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical progression sings</measure>
    <time_frame>6 weeks</time_frame>
    <description>After the first application time: White transperent color of granulation tissue appeared.
After the second application time: color dense of granulation tissue increased and covered all over the wound.
After the third application time: granulation tissue thickness increased and appeared as a complete homogenous layer.
After the fourth application time: depending on lesion depth and size, granulation tissue turned to be pink to red color.
After the fifth and sexth application time: Skin layers development appeared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient complain (upon the weekly questionnaire)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The quality of life is scored 0 (minimum) -100 (maximum), the pain reduction is scored 0-100 (as previous) from the first visit till 6 weeks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Epidermolysis Bullosa</condition>
  <condition>Chronic Skin Ulcer</condition>
  <arm_group>
    <arm_group_label>Treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who received REGE pro dressing on EB wounds lesion weekly for 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REGE pro dressing</intervention_name>
    <description>REGE pro is a dressing of dried human amniotic membrane sterilized by gamma radiation</description>
    <arm_group_label>Treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1- Patients diagnosed as EB wounds must be chronic

        Exclusion Criteria:

          1. Patients Must stop other line of treatment

          2. Exclude patients have:

               1. Autoimmune diseases

               2. Diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nashwa K Radwan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amniotic tissue lab</name>
      <address>
        <city>Cairo</city>
        <zip>29</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Nemr W, Bashandy AS, Araby E, Khamiss O. Biological Activity Alterations of Human Amniotic Membrane Pre and Post Irradiation Tissue Banking. Pak J Biol Sci. 2016;19(7):289-298. doi: 10.3923/pjbs.2016.289.298.</citation>
    <PMID>29023030</PMID>
  </reference>
  <results_reference>
    <citation>Lo V, Lara-Corrales I, Stuparich A, Pope E. Amniotic membrane grafting in patients with epidermolysis bullosa with chronic wounds. J Am Acad Dermatol. 2010 Jun;62(6):1038-44. doi: 10.1016/j.jaad.2009.02.048.</citation>
    <PMID>20466177</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>June 26, 2019</last_update_submitted>
  <last_update_submitted_qc>June 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Egyptian Atomic Energy Authority</investigator_affiliation>
    <investigator_full_name>Nashwa Radwan</investigator_full_name>
    <investigator_title>Head of amniotic tissue laboratory, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Epidermolysis Bullosa</keyword>
  <keyword>Amniotic membrane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
    <mesh_term>Skin Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

